End of life distress as an economic issue: The case for psychedelic-assisted therapy - ERRATUM.

Michel Dorval; Virginie Audet-Croteau; Sue-Ling Chang; Florence Moureaux; Jason Robert Guertin

doi:10.1017/s1478951526101771

End of life distress as an economic issue: The case for psychedelic-assisted therapy - ERRATUM.

Michel Dorval, Virginie Audet-Croteau, Sue-Ling Chang, Florence Moureaux, Jason Robert Guertin

Palliative & Supportive Care March 10, 2026 DOI: 10.1017/s1478951526101771 (opens in new tab)

Read Full Text

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	End-of-life distress Psychedelic-assisted therapy

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

End of life distress as an economic issue: The case for psychedelic-assisted therapy. Palliative & Supportive Care January 28, 2026
Psychedelic-assisted psychotherapy for existential suffering: Facilitating self-transcendence at the end of life. International Journal of Transpersonal Studies March 18, 2022
Psychedelic therapy at the end of life: unexplored alternative to assisted suicide in the UK. The British Journal of Psychiatry July 14, 2026
Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care. Neuropharmacology September 15, 2022 69 citations
Barriers and Facilitators to the Equitable Access of Psychedelic Medical Care and Research in Alzheimer’s Disease and Related Dementias AJOB Neuroscience April 3, 2023

Explore topics

End-of-life distress Psychedelic-assisted therapy

Study at a glance

Abstract

Related reading

Explore topics